Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Terminated
This phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the grow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2015
Locations: Union Hospital of Cecil County, Elkton MD, Maryland
Conditions: Refractory Multiple Myeloma
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Completed
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: The John R Marsh Cancer Center, Hagerstown, Maryland
Conditions: Chemotherapy-Induced Nausea and Vomiting
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2014
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
Completed
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2014
Locations: Annapolis Oncology Center, Annapolis, Maryland +8 locations
Conditions: Multiple Myeloma
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
Completed
The purpose of this study is to evaluate the effectiveness and safety of trabectedin in 3 subpopulations of participants with previously treated progressive metastatic ( spread of a cancer from one organ or part to another non-adjacent organ or part) breast cancer (abnormal tissue that grows and spreads in the body until it kills) participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2014
Locations: Not set, Westminster, Maryland
Conditions: Breast Neoplasms
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Terminated
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/02/2014
Locations: University of Maryland, Baltimore, Maryland +1 locations
Conditions: Immune Thrombocytopenic Purpura
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Unknown
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving bortezomib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how wel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2013
Locations: Center for Cancer and Blood Disorders, Bethesda, Maryland
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/19/2013
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Leukemia, Lymphoma
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
03/28/2013
Locations: Wilmer Eye Institute, Baltimore, Maryland
Conditions: Anterior Uveitis
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
Completed
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
01/31/2013
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Leukemia
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Completed
The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2013
Locations: Not set, Baltimore, Maryland
Conditions: Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Baltimore, Maryland +1 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced